- Home
- JBGS vs XERS Comparison
JBGS vs XERS Comparison
Compare JBGS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 936.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBGS | XERS |
|---|---|---|
| Price | $14.98 | $5.43 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $17.00 | $10.83 |
| AVG Volume (30 Days) | 496.3K | ★ 2.1M |
| Earning Date | 04-28-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $28.65 |
| Revenue Next Year | N/A | $18.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $13.28 | $3.81 |
| 52 Week High | $24.30 | $10.08 |
Technical Indicators
Market Signals| Indicator | JBGS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 32.22 |
| Support Level | $14.21 | $4.30 |
| Resistance Level | $15.95 | $5.49 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 79.58 | 8.47 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.